FULC Fulcrum Therapeutics Inc

Price (delayed)

$8.59

Market cap

$280.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.53

Enterprise value

$178.88M

Highlights
The equity has soared by 81% YoY and by 34% from the previous quarter
The company's EPS has surged by 71% YoY and by 9% QoQ
Fulcrum Therapeutics's net income has decreased by 8% YoY but it has increased by 2.1% from the previous quarter

Key stats

What are the main financial stats of FULC
Market
Shares outstanding
32.68M
Market cap
$280.72M
Enterprise value
$178.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.2
Price to sales (P/S)
21.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.91
Earnings
Revenue
$12.86M
EBIT
-$69.37M
EBITDA
-$66.92M
Free cash flow
-$55.71M
Per share
EPS
-$2.53
Free cash flow per share
-$1.77
Book value per share
$3.91
Revenue per share
$0.41
TBVPS
$4.97
Balance sheet
Total assets
$156.48M
Total liabilities
$28.72M
Debt
$0
Equity
$127.75M
Working capital
$124.36M
Liquidity
Debt to equity
0
Current ratio
6.49
Quick ratio
6.43
Net debt/EBITDA
1.52
Margins
EBITDA margin
-520.3%
Gross margin
100%
Net margin
-539.3%
Operating margin
-543.1%
Efficiency
Return on assets
-48.4%
Return on equity
-61.7%
Return on invested capital
-173.1%
Return on capital employed
-51.8%
Return on sales
-539.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FULC stock price

How has the Fulcrum Therapeutics stock price performed over time
Intraday
0.23%
1 week
-0.35%
1 month
-13.14%
1 year
-58.12%
YTD
-26.64%
QTD
-27.08%

Financial performance

How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$12.86M
Gross profit
$12.86M
Operating income
-$69.86M
Net income
-$69.37M
Gross margin
100%
Net margin
-539.3%
The net margin has soared by 94% YoY and by 33% from the previous quarter
Fulcrum Therapeutics's operating margin has soared by 94% YoY and by 33% from the previous quarter
Fulcrum Therapeutics's gross profit has increased by 46% from the previous quarter
The revenue has grown by 46% from the previous quarter

Growth

What is Fulcrum Therapeutics's growth rate over time

Valuation

What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
2.2
P/S
21.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.91
The company's EPS has surged by 71% YoY and by 9% QoQ
The equity has soared by 81% YoY and by 34% from the previous quarter
FULC's P/B is 27% below its last 4 quarters average of 3.0
The price to sales (P/S) is 69% lower than the last 4 quarters average of 67.0
The revenue has grown by 46% from the previous quarter

Efficiency

How efficient is Fulcrum Therapeutics business performance
The company's return on sales has surged by 94% YoY and by 33% QoQ
Fulcrum Therapeutics's ROE has soared by 67% YoY and by 14% from the previous quarter
FULC's return on invested capital has surged by 55% year-on-year but it is down by 12% since the previous quarter
Fulcrum Therapeutics's ROA has increased by 32% YoY and by 13% from the previous quarter

Dividends

What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FULC.

Financial health

How did Fulcrum Therapeutics financials performed over time
FULC's total assets has soared by 65% year-on-year and by 21% since the previous quarter
Fulcrum Therapeutics's quick ratio has increased by 47% from the previous quarter and by 10% YoY
The debt is 100% less than the equity
The equity has soared by 81% YoY and by 34% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.